MYCN and neoplasm: Accordingly, type 1 displays high TrkA expression, low-risk tumour, and triploid DNA content; 2A comprises intermediate-risk tumours, frequent 11q deletions, and 17q gain with no MYCN-amplification; while 2B comprises high-risk tumours with MYCN amplification, a high frequency of 1p deletions, and 17q gains [30,31].